Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre Oscar Lambret
AstraZeneca
Cancer Research UK
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Amgen
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Research UK
Novartis
Milton S. Hershey Medical Center
Ikena Oncology
Hutchmed
Eli Lilly and Company
Institut du Cancer de Montpellier - Val d'Aurelle
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Aminex Therapeutics, Inc.
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
University Health Network, Toronto
University of Southern California
Deciphera Pharmaceuticals, LLC
Novartis
Five Prime Therapeutics, Inc.
Weill Medical College of Cornell University
Celgene
Shenzhen BinDeBio Ltd.
Polaris Group
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Emory University
Southwest Hospital, China
Shenzhen BinDeBio Ltd.
Masonic Cancer Center, University of Minnesota
Chang Gung Memorial Hospital
Chinese PLA General Hospital
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Case Comprehensive Cancer Center